Markers of bladder cancer diagnosis and prognosis will be developed and evaluated as part of the NCI Bladder Tumor Marker Network. Candidate markers will be selected based on clinical significant in a phased approach, starting with small pilot studies at UCSF to define assay conditions, test prevalence, and determine clinical significant Studies will then be proposed for the full Network using material from Member tissue banks. Markers will be considered for clinical application based on their biology, and will be tested for clinical significance in a defined context. Areas of need for prognostic markers include: prediction of recurrence or progression in superficial disease; prediction of metastasis in invasive cancer; and prediction of response to therapy. Network studies will have highest priority. Specimen acquisition of prospective and retrospective material will occur at UCSF Moffitt, Mt. Zion and SFVA medical centers. UCSF has been responsible for Network analyses of Proliferation (Ki67), angiogenesis, and molecular cytogenetics (FISH). These activities will continue, with additional responsibility for coordinating correlative superficial tumor marker studies in collaboration with the South West Oncology Group (SWOG). UCSF will also continue to coordinate quality control studies to define sources of variation in interlaboratory comparisons of molecular cytogenetics and proliferative immunohistochemistry assays. Molecular cytogenetic assays will be the focus of marker developments. Fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) will be used to define markers of tumor progression l) Abnormalities in the bladder field will be examined by centromeric FISH analysis of exfoliated cells and of grossly normal appearing biopsies from patients with concurrent tumors. 2) CGH will be used to define clonal relationships between multiple or recurrent tumors to distinguish tumor spread vs. a field defect as their cause. 3) Section FISH and CGH will be used to identify early genetic changes in premalignant disease (CIS and dysplasia) 4) CGH will be used to identify chromosomal alterations which are more fluent in tumor metastases than primaries in paired samples. 5) CGH will be used to link overall levels of DNA gains and losses (genetic instability) with clinical outcome in invasive tumors. 6) Amplification of chromosome 20q will be detected by FISH to evaluate the potential significance of this newly defined genetic abnormality.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (07))
Program Officer
Aamodt, Roger L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Wilhelm, Monica; Veltman, Joris A; Olshen, Adam B et al. (2002) Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res 62:957-60
Moore, Lee E; Smith, Allan H; Eng, Clarence et al. (2002) Arsenic-related chromosomal alterations in bladder cancer. J Natl Cancer Inst 94:1688-96
Orntoft, Torben F; Thykjaer, Thomas; Waldman, Frederic M et al. (2002) Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. Mol Cell Proteomics 1:37-45
Albert, P S; McShane, L M; Shih, J H et al. (2001) Latent class modeling approaches for assessing diagnostic error without a gold standard: with applications to p53 immunohistochemical assays in bladder tumors. Biometrics 57:610-9
Muscheck, M; Abol-Enein, H; Chew, K et al. (2000) Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization. Carcinogenesis 21:1721-6
Baehner, R; Magrane, G; Balassanian, R et al. (2000) Donor origin of neuroendocrine carcinoma in 2 transplant patients determined by molecular cytogenetics. Hum Pathol 31:1425-9
Hovey, R M; Chu, L; Balazs, M et al. (1998) Genetic alterations in primary bladder cancers and their metastases. Cancer Res 58:3555-60
Chudek, J; Herbers, J; Wilhelm, M et al. (1998) The genetics of renal tumors in end-stage renal failure differs from those occurring in the general population. J Am Soc Nephrol 9:1045-51
Wagner, U; Bubendorf, L; Gasser, T C et al. (1997) Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol 151:753-9
Willenbucher, R F; Zelman, S J; Ferrell, L D et al. (1997) Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology 113:791-801

Showing the most recent 10 out of 38 publications